Ascend Capital LLC reduced its holdings in shares of Mylan (NASDAQ:MYL) by 21.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,053,594 shares of the company’s stock after selling 562,909 shares during the period. Mylan comprises about 3.3% of Ascend Capital LLC’s investment portfolio, making the stock its biggest position. Ascend Capital LLC’s holdings in Mylan were worth $86,888,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of MYL. Meeder Asset Management Inc. boosted its position in Mylan by 76.9% in the third quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after buying an additional 1,475 shares in the last quarter. Nationwide Fund Advisors boosted its position in Mylan by 4.8% in the third quarter. Nationwide Fund Advisors now owns 461,279 shares of the company’s stock valued at $14,470,000 after buying an additional 21,184 shares in the last quarter. Rothschild Investment Corp IL boosted its position in Mylan by 19.8% in the third quarter. Rothschild Investment Corp IL now owns 15,370 shares of the company’s stock valued at $482,000 after buying an additional 2,540 shares in the last quarter. Integrated Investment Consultants LLC boosted its position in Mylan by 26.7% in the third quarter. Integrated Investment Consultants LLC now owns 54,055 shares of the company’s stock valued at $1,696,000 after buying an additional 11,400 shares in the last quarter. Finally, Crossmark Global Holdings Inc. acquired a new position in Mylan in the third quarter valued at about $566,000. Institutional investors and hedge funds own 76.86% of the company’s stock.
Mylan (NASDAQ:MYL) opened at $41.78 on Tuesday. Mylan has a 12 month low of $29.39 and a 12 month high of $47.82. The firm has a market cap of $22,240.00, a PE ratio of 25.17, a price-to-earnings-growth ratio of 1.12 and a beta of 1.35. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $3,375,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.69% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3224800/ascend-capital-llc-sells-562909-shares-of-mylan-myl.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.